Integra LifeSciences prices $450M in 9.5% secured notes

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes at a 9.5% interest rate, with a maturity date set for 2033. The notes, which are general senior secured obligations, are guaranteed by Integra’s wholly-owned domestic subsidiaries. The company intends to utilize the proceeds from this note offering, along with new borrowings, to refinance existing credit facilities and cover related expenses.

The sale, subject to customary closing conditions, is expected to close on or around October 19, 2026. These notes are exclusively offered to qualified institutional buyers under Rule 144A of the Securities Act of 1933, and to certain non-U.S. persons outside the United States under Regulation S. Integra LifeSciences specializes in neurosurgery and tissue reconstruction products.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.